Molecular Partners Ag's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Molecular Partners Ag (MOLN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Molecular Partners Ag vs Its Competitors
- TTM: Trailing 12-month revenue of 5M vs 180,262M combined for its competitors (0.0% combined share).
- Scale: Molecular Partners Ag ranks #98 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.04M compares with $1.18M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Molecular Partners Ag vs. its Competitors, Q4 2025
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Molecular Partners Ag reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Molecular Partners Ag and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Molecular Partners Ag | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Molecular Partners Ag's competitor groups requires a Commercial License.
Molecular Partners Ag's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Molecular Partners Ag | - | - | - | Yes |
| Competitors combined (64) | ||||
| High-Confidence Competitors (6) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MOLN Stock Performance relative to its Competitors
MOLN Stock Performance relative to High-Confidence Competitors
MOLN Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Immunitybio inc | 282.9% | Outperformed |
| 4 | Revolution Medicines Inc | 282.9% | Outperformed |
| 5 | Vir Biotechnology Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Molecular Partners Ag's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Molecular Partners Ag's Comment on Competition and Industry Peers
Publicly Traded Peers of Molecular Partners Ag
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Molecular Partners Ag |
115.17 | 4.97 |
 Novartis Ag |
319,173.30 | 56,674.00 |
 Amgen Inc |
254,015.58 | 38,903.00 |
 Gilead Sciences Inc |
213,758.37 | 30,988.00 |
 Vertex Pharmaceuticals Inc |
139,821.53 | 12,951.60 |
 Moderna Inc |
99,830.34 | 2,228.00 |
| SUBTOTAL | 1,320,139.64 | 180,300.07 |
Sign in to see all competitors of Molecular Partners Ag.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Molecular Partners Ag versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Molecular Partners Ag's Competitors Named by the Company
Competitive relationships identified from Molecular Partners Ag reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Aptevo Therapeutics Inc | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Pfizer, Inc. | Company report | 85% |
| Eli Lilly | Company report | 85% |
Company report basis, confidence, active dates and source counts for Molecular Partners Ag's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Molecular Partners Ag's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Molecular Partners Ag.
Molecular Partners Ag's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Molecular Partners Ag | 115 | 38,231 | -572,438 |
| Novartis Ag | 319,173 | 752,973 | 185,566 |
| Amgen Inc | 254,016 | 2,992,538 | 722,385 |
| Gilead Sciences Inc | 213,758 | 1,822,824 | -227,235 |
| Vertex Pharmaceuticals Inc | 139,822 | 31,979,259 | 9,817,037 |
| Moderna Inc | 99,830 | 474,043 | -670,426 |
| PEERS TOTAL | 1,320,024 | 1,177,991 | 115,430 |
Sign in to see all peers for Molecular Partners Ag.
Molecular Partners Ag's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Exelixis Inc | United States 92.47 % |
| Immunitybio inc | United States 99.79 % |
| Iovance Biotherapeutics inc | US 98.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Molecular Partners Ag.
Molecular Partners Ag's Position in Industry Market Structure
Market-capitalization share and concentration across all 157 companies in Molecular Partners Ag's industry classification, broader than the peer set above. Market cap in millions of $.Molecular Partners Ag ranks #98 of 157 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,408, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 253,085 | 26.48 % |
| 2 | Gilead Sciences Inc | 212,391 | 22.23 % |
| 3 | Moderna Inc | 99,830 | 10.45 % |
| 4 | Argenx Se | 64,151 | 6.71 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Kymera Therapeutics Inc | 1,234 | 5.2% |
| 98 | Molecular Partners Ag | 115 | 0.01 % |
Market cap and industry share for the rest of Molecular Partners Ag's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Molecular Partners Ag's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 93 | Liminatus Pharma Inc | 134 | 140.34 % |
| 94 | Innate Pharma Sa | 130 | -16.34 % |
| 95 | Lenz Therapeutics Inc | 129 | -82.24 % |
| 96 | Atara Biotherapeutics Inc | 122 | - |
| 97 | Engene Therapeutics Inc | 1,234 | 12.3% |
| 98 | Molecular Partners Ag | 115 | - |
| 99 | Cellectis S a | 1,234 | 12.3% |
| 100 | Voyager Therapeutics Inc | 1,234 | 12.3% |
| 101 | Anavex Life Sciences Corp | 1,234 | 12.3% |
| 102 | Coherus Oncology inc | 1,234 | 12.3% |
| 103 | Leonabio Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Molecular Partners Ag's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Molecular Partners Ag's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.6x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 1.5x | 5.3x | -3.8x |
| Return on Equity | -73.51 % | industry aggregate | -83.88 % |
| Return on Invested Capital | -32.91 % | -10.86 % (avg) | -22.05 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Molecular Partners Ag's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -96.05 % | -27.97 % | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | -15.93 % | -21.83 % | -32.91 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Molecular Partners Ag's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Molecular Partners Ag falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Molecular Partners Ag's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,408 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Molecular Partners Ag's dedicated Suppliers and Customers pages, not here.
Molecular Partners Ag's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Molecular Partners Ag falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Molecular Partners Ag's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 83.9 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (64.10 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Molecular Partners Ag's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Molecular Partners Ag | 7.50 | 8.79 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
Sign in to see all peers for Molecular Partners Ag.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Molecular Partners Ag's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Molecular Partners Ag | Q4 2025 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| PEERS TOTAL | +11.2 % | +5.0 % |
Sign in to see all peers for Molecular Partners Ag.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Molecular Partners Ag's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Molecular Partners Ag | Q4 2025 | - | +7.6 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
Sign in to see all peers for Molecular Partners Ag.
Molecular Partners Ag's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Molecular Partners Ag | - | - | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Gilead Sciences Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Moderna Inc | - | - | - |
Sign in to see all peers for Molecular Partners Ag.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Molecular Partners Ag's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Molecular Partners Ag | - | 23.17 |
| Novartis Ag | 22.82 | 5.63 |
| Amgen Inc | 26.97 | 6.53 |
| Gilead Sciences Inc | - | 6.90 |
| Vertex Pharmaceuticals Inc | 35.32 | 10.80 |
| Moderna Inc | - | 44.81 |
| PEERS AVERAGE | 75.04 | 7.32 |
Sign in to see all peers for Molecular Partners Ag.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.